Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.
Wayne Gretzky hung up his hockey sticks a long time ago. Although Gretzky's quote has become something of a cliche, it nonetheless remains highly relevant in many areas -- including investing. For investors, the idea is the same concept that Gretzky articulated years ago: Focus on what's going to happen in the future.
BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain. The service is expected to become operational in
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021.
Guardant Health ([[GH]] +1.1%) will launch the first liquid biopsy test for detection of early-stage colon cancer recurrence in February, CEO Helmy Eltoukhy said. The test will be called Guardant Reveal.Reveal will have a seven-day turnaround time, Eltoukhy said in an interview. Additional cancer types to follow.The company also expects to...